K. Hazell

发表

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2012, Leukemia & lymphoma.

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Suzanne F. Jones, J. Baselga, F. Rojo, 2005 .

Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers.

I. Judson, C. Brock, N. Shand, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).

S. Lonial, J. S. San Miguel, M. Mateos, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2008 .

Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State

G. Bruin, F. Waldmeier, J. Porter, 2010, Drug Metabolism and Disposition.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Suzanne F. Jones, F. J. Ramos, J. Baselga, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

D. Csonka, L. Trandafir, Z. Kobalava, 2015, Journal of clinical pharmacology.

Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers

L. Trandafir, P. Swart, A. Jakab, 2015, Cancer Chemotherapy and Pharmacology.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

H. Lane, E. Raymond, J. Kovarik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Suzanne F. Jones, Ian Judson, D. Rea, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.

Yi-long Wu, Bing-he Xu, L. Trandafir, 2016, Anticancer research.

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

D. Siegel, P. Richardson, O. Sezer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

S. Lonial, T. Facon, J. San-Miguel, 2010 .

Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus).

J. Baselga, I. Judson, H. Burris, 2006, Journal of Clinical Oncology.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

H. Lane, E. Raymond, J. Kovarik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.